# Calcium Integrated Physiology and Disorders

## Introduction: The Calcium Axis

Calcium homeostasis is maintained through a tightly coordinated feedback loop involving three target organs (parathyroid glands, kidneys, intestine) and two hormones (parathyroid hormone \[PTH\] and active vitamin D \[1,25-dihydroxyvitamin D\]) \[1\]. A comprehensive understanding of this axis is essential for board-level nephrology practice.

Key Point

Serum calcium represents only 0.1% of total body calcium; 99% is stored in bone. However, the small extracellular pool maintains critical neuromuscular and cardiac function.

## Calcium Distribution and Measurement

### Total vs. Ionized Calcium

| Calcium Fraction | Percentage | Pathophysiology |
|----|----|----|
| **Ionized (free)** | 45–50% | Physiologically active; unaffected by albumin |
| **Protein-bound** | 40–45% | Bound mostly to albumin; decreases in hypoalbuminemia |
| **Complexed** | 5–10% | Bound to citrate, phosphate; increases in acidosis |

**Clinical Pearl:** When albumin is low, measured total calcium falls 0.8 mg/dL per 1 g/dL albumin decrease, but ionized calcium (and symptoms) may be normal.

### Corrected Calcium Formula \[2\]

**Corrected Ca = Measured Ca + 0.8 × (4.0 – measured albumin \[g/dL\])**

Example: Patient with measured Ca 7.2 mg/dL and albumin 2.0 g/dL - Corrected Ca = 7.2 + 0.8 × (4.0 – 2.0) = 7.2 + 1.6 = 8.8 mg/dL (likely normal ionized Ca)

Clinical Pearl

When corrected calcium is normal but symptoms suggest hypocalcemia (paresthesias, tetany), measure ionized calcium directly. Alkalemia increases calcium binding and can lower ionized calcium despite a normal total calcium. Severe magnesium deficiency can also cause hypocalcemia through impaired PTH secretion/action.

## Normal Calcium Homeostasis Physiology

### The Negative Feedback Loop

**Step 1:** Serum calcium decreases (\< 8.5 mg/dL) - Calcium-sensing receptor (CaSR) on parathyroid cells detects low Ca - PTH secretion increases immediately

**Step 2:** PTH acts on three target sites: - **Kidney (proximal tubule):** Activates 1α-hydroxylase → increases 1,25-(OH)2D (calcitriol) - **Kidney (distal tubule):** Increases calcium reabsorption via TRPV5 channels - **Bone:** Stimulates osteoclasts → releases Ca and phosphate

**Step 3:** Calcitriol increases intestinal calcium absorption (duodenum/jejunum)

**Step 4:** Serum calcium normalizes → CaSR senses high Ca → PTH suppressed

### FGF-23 and Mineral Homeostasis

In chronic kidney disease, the axis becomes dysregulated: - **Early CKD:** Phosphate retention stimulates FGF-23 production - **FGF-23 suppresses:** 1α-hydroxylase (less calcitriol) and PTH (via Klotho co-receptor) - **Later CKD:** Secondary hyperparathyroidism develops as GFR \< 45 and 1,25-D falls critically

## Hypercalcemia: Differential Diagnosis and Approach \[3\]

### PTH-Dependent Hypercalcemia (5–10% of cases)

| Condition | PTH | 1,25-D | Urine Ca | Mechanism |
|----|----|----|----|----|
| **1° Hyperparathyroidism** | High | Normal/↑ | ↑ (usually) | Adenoma/hyperplasia, loss of CaSR set point |
| **Familial Hypocalciuric Hypercalcemia (FHH)** | Normal/↑ | Normal | **↓** (\< 150 mg/24h) | Usually loss-of-function calcium-sensing receptor signaling in FHH1; reduced calcium sensing permits hypercalcemia with relative hypocalciuria. |

**FHH Pearl:** Always check urine calcium; FHH presents with **hypercalcemia + hypocalciuria** (opposite of 1° hyperparathyroidism). PTH may be inappropriately high for calcium level.

### PTH-Independent Hypercalcemia (90% of cases)

#### Non-PTH-Mediated Humoral Hypercalcemia (PTHrP-Mediated)

- **PTHrP-producing malignancies:** Squamous cell lung, renal, ovarian, breast cancers
- PTHrP increases bone resorption and renal calcium retention. Humoral hypercalcemia of malignancy is distinct from calcitriol-mediated hypercalcemia.
- Key finding: Hypercalcemia with suppressed PTH and elevated PTHrP; calcitriol is usually suppressed rather than predictably elevated.

#### Calcitriol-Producing Hypercalcemia (1,25-D-Mediated)

- **Granulomatous diseases:** Sarcoidosis, TB, histoplasmosis, coccidioidomycosis, berylliosis
- **Lymphomas:** Especially Hodgkin, non-Hodgkin with extragonadal germ cell origin
- **Mechanism:** Granuloma macrophages or malignant lymphocytes produce 1α-hydroxylase (unregulated)
- **Key finding:** High Ca, low PTH, **elevated 1,25-D** (unregulated activation)

#### Osteolytic Hypercalcemia (local bone resorption)

- **Metastatic bone disease:** Breast cancer with bone mets producing IL-6, TNF-α
- **Multiple myeloma:** Osteoclast activation via RANKL
- Mechanism: Tumor-related local cytokines and osteoclast activation increase bone resorption; calcitriol excess is a separate mechanism.
- Key finding: Hypercalcemia with suppressed PTH; use the malignancy evaluation and relevant tests rather than assuming elevated calcitriol.

#### Vitamin D Intoxication and Vitamin A Intoxication

- **Vitamin D:** Iatrogenic (over-supplementation), granulomatous production
- **Vitamin A:** Chronic excess from supplements, retinoids
- **Different mechanisms:** Vitamin D excess increases intestinal calcium absorption; excess preformed vitamin A can cause bone resorption and hypercalcemia. Review supplement and retinoid exposure. [Experimental bone-resorption evidence](https://pubmed.ncbi.nlm.nih.gov/3371268/).

### Diagnostic Algorithm for Hypercalcemia

    Confirmed hypercalcemia
    1. Verify calcium status; use ionized calcium when albumin correction is unreliable or clinical findings disagree.
    2. Measure PTH. An inappropriately nonsuppressed PTH suggests PTH-dependent disease; assess primary hyperparathyroidism versus FHH using history, urine calcium and confounders, with genetic evaluation when indicated.
    3. Suppressed PTH suggests another mechanism. Evaluate medication/supplement exposure, malignancy, PTHrP, 25-OH vitamin D and calcitriol as clinically indicated.
    4. Elevated calcitriol suggests lymphoma or granulomatous disease; elevated PTHrP supports humoral malignancy-related hypercalcemia. Neither marker must be high in osteolytic disease.
    5. Do not diagnose FHH or a malignancy mechanism from one isolated cutoff.

## Hypocalcemia: Differential Diagnosis and Approach

### PTH Response in Hypocalcemia

| Category | PTH | 1,25-D | Phosphate | Cause |
|----|----|----|----|----|
| **PTH Deficiency** | Low | Low | High | Post-surgical, autoimmune, infiltrative |
| **PTH Resistance** | High | Normal/Low | **High** | CKD, pseudohypoparathyroidism (PHP), hypomagnesemia |
| **1,25-D Deficiency** | High | Low | Normal/High | CKD stage 3–5, vitamin D malabsorption, dietary lack |

High-Yield Board Point

Hypomagnesemia (\< 1.5 mg/dL) suppresses both PTH secretion AND PTH action on kidneys. Always replete magnesium in patients with refractory hypocalcemia.

### Common Causes of Hypocalcemia \[4\]

#### Acute Hypocalcemia (\< 7.0 mg/dL)

- **Acute pancreatitis:** Saponification of fat; severe
- **Tumor lysis syndrome:** Phosphate released → Ca precipitates; acute, life-threatening
- **Sepsis/Critical illness:** Reduced 1,25-D production, increased FGF-23
- **Blood transfusion (massive):** Citrate binds Ca

#### Chronic Hypocalcemia

- **CKD stages 3–5:** Phosphate retention + loss of 1α-hydroxylase function
- **Vitamin D deficiency:** Malabsorption, insufficient sun exposure, dietary lack
- **Hypoparathyroidism:** Post-thyroidectomy/parathyroidectomy, autoimmune, infiltrative (infiltration granulomas, iron, amyloid)
- **Pseudohypoparathyroidism:** Tissue resistance to PTH; PTH high but ineffective

#### Hungry Bone Syndrome

- **Setting:** Post-parathyroidectomy, post-thyroidectomy, or after stopping PTH treatment
- Mechanism: After abrupt reduction of high PTH-driven turnover, continued bone mineral uptake can cause sustained calcium, phosphate and magnesium depletion (hungry bone syndrome).
- **Prevention:** Careful post-operative monitoring, IV calcium if severe

### Symptoms and Emergency Management

| Severity | Ca Level | Symptoms | Management |
|----|----|----|----|
| **Mild** | 7.0–8.5 | Paresthesias, muscle cramps | Oral supplementation |
| **Moderate** | 6.5–7.0 | Tetany, positive Chvostek/Trousseau | IV calcium + oral |
| **Severe** | \< 6.5 | Seizures, laryngeal spasm, arrhythmias | **Urgent IV calcium** |

Acute IV calcium: For severe symptomatic adult hypocalcemia, the Society for Endocrinology protocol uses 10–20 mL of 10% calcium gluconate diluted in 50–100 mL fluid over 10 minutes with ECG monitoring, then reassessment and an individualized infusion if needed. Ten mL contains 1 g calcium gluconate salt, approximately 93 mg elemental calcium—not 1 g elemental calcium. Calcium chloride has a different elemental content and extravasation risk; do not substitute volume-for-volume.

## CKD-Mineral Bone Disease (CKD-MBD): The Integrated Picture \[5\]

### The Vicious Cycle in CKD

CKD G3a–G3b (eGFR 45–59 and 30–44): Mineral/hormonal adaptation may precede elevated serum phosphate. Begin recommended monitoring; do not equate eGFR below 60 with G3b.

CKD G4 (eGFR 15–29): Reduced calcitriol and phosphate retention can contribute to secondary hyperparathyroidism. Assess measured calcium/phosphate/PTH trends rather than assuming a fixed sequence at eGFR 45.

**GFR \< 15 (CKD Stage 5):** - Severe hyperparathyroidism, bone disease, vascular calcification - Risk of cardiac arrhythmias, fracture, cardiovascular death

### CKD-MBD Management Targets (KDIGO 2017)

| Stage | Target PTH | Target Phosphate | Target Calcium |
|----|----|----|----|
| **3b–4** | Optimal PTH is unknown in nondialysis CKD; evaluate persistent/progressive elevation and modifiable factors. | 2.5–4.5 mg/dL | 8.5–10.5 mg/dL |
| **5D (dialysis)** | Approximately 2–9 times the assay upper limit in G5D; interpret trends and avoid oversuppression. | Lower persistently elevated phosphate toward the normal range; individualize. | 8.5–10.5 mg/dL |

Clinical Pearl

Start monitoring in G3a, but do not prescribe prophylactic phosphate binders or routine active vitamin D in normophosphatemic adult nondialysis CKD. Address documented abnormalities and reserve active vitamin D in G4–G5 for severe, progressive hyperparathyroidism after correcting modifiable factors.

### Calcium-Phosphorus Product (CaxP)

**CaxP = Serum Ca × Serum PO4** (both in mg/dL)

Current KDIGO approach: Use individual calcium and phosphate values together with PTH trends; a calcium–phosphate product below 55 is not a treatment target.

**Clinical significance:** Products \> 70 associated with increased vascular and soft-tissue calcification

## Treatment of Hypercalcemia: Board-Level Approach

| Severity | Acute Management | Long-Term |
|----|----|----|
| **Mild (10.5–12 mg/dL), Asymptomatic** | Hydration if dehydrated; dietary Ca restriction | Treat underlying cause |
| **Moderate (12–14 mg/dL), Symptomatic** | Isotonic fluid for volume depletion, titrated to perfusion and overload risk; urgent cause-specific assessment. | Treat the cause; consider parathyroid surgery for eligible primary hyperparathyroidism and mechanism-directed treatment for malignancy or calcitriol excess. Thiazides can worsen hypercalcemia. |
| **Severe (\> 14 mg/dL), Life-Threatening** | Urgent monitored treatment: volume-appropriate isotonic fluid and cause-specific therapy; for malignancy-related disease consider antiresorptive treatment and short-course calcitonin when indicated, accounting for kidney function. | Parathyroidectomy (1° HPT), definitive cancer treatment |

### Drug-Specific Interventions

| Cause | First-Line | Alternative | Rationale |
|----|----|----|----|
| **1° Hyperparathyroidism** | Parathyroidectomy | Cinacalcet (CaSR agonist) | Definitive; partial in cinacalcet |
| **Sarcoidosis** | Corticosteroids | Hydroxychloroquine | Reduce granuloma macrophage 1α-hydroxylase |
| **Vitamin D Intoxication** | Corticosteroids | Monitor; restriction | Inhibit 1α-hydroxylase activity |
| **Lymphoma/PTHrP malignancy** | Chemotherapy | Bisphosphonates | Treat cancer; symptomatic relief |
| **Immobilization** | Mobilization | Hydration | Restore normal bone turnover |

## Treatment of Hypocalcemia: Board-Level Approach

### Asymptomatic Hypocalcemia (\> 7.0 mg/dL, no symptoms)

- **Oral supplements:** Calcium citrate 2–4 g/day divided TID (with meals for absorption)
- Vitamin D: Treat nutritional vitamin D deficiency appropriately; use active vitamin D for a specific indication such as hypoparathyroidism, not routinely for every patient with CKD.
- **Monitor:** Ionized Ca, ECG, renal function

### Symptomatic Hypocalcemia (\< 7.0 mg/dL or paresthesias/tetany)

- IV calcium gluconate: Use the monitored adult emergency regimen above, reassess symptoms and ionized calcium, and individualize further bolus or infusion therapy.
- After stabilization: Continue an individualized calcium infusion or oral regimen according to symptoms and repeated calcium measurements; account for kidney function and the underlying cause.
- Magnesium: Correct documented deficiency using kidney-aware doses and repeated measurements; avoid forcing every patient above a universal numerical target.

### Hypoparathyroidism Management

- Active vitamin D: For hypoparathyroidism, select and titrate calcitriol with oral calcium using symptoms, calcium/phosphate and urinary calcium; avoid a universal high-dose schedule.
- Thiazides can reduce urinary calcium excretion in selected patients with hypoparathyroidism and hypercalciuria; monitor blood pressure, potassium, magnesium and serum calcium.
- **Low phosphate diet:** Reduces PTH stimulus

### CKD Hypocalcemia Management

- Vitamin D in CKD: Correct nutritional deficiency; active vitamin D is not routine nondialysis therapy and requires a defined indication with calcium/phosphate monitoring.
- **Phosphate binders:** Non-calcium-based (sevelamer, lanthanum) preferred in later CKD
- **Monitor PTH:** Serial measurements guide intensity of therapy

High-Yield Board Point

In severe symptomatic hypocalcemia, give IV calcium even if total calcium is borderline normal—ionized Ca may be severely low. Never withhold treatment waiting for labs if tetany or seizures present.

## Clinical Vignettes

### Vignette 1: Asymptomatic Hypercalcemia

A 68-year-old woman is found to have Ca 11.2 mg/dL on routine labs. PTH 8 pg/mL (low), 1,25-D 22 pg/mL (low), albumin normal. 15-year history of sarcoidosis on chronic prednisone.

Interpretation: PTH is suppressed, but low calcitriol does not support active calcitriol-mediated sarcoid hypercalcemia. Reconfirm calcium and review medications/supplements and other PTH-independent causes; do not increase prednisone solely because of the sarcoidosis history.

### Vignette 2: Severe Symptomatic Hypocalcemia

A 56-year-old man post-total thyroidectomy develops severe tetany (Trousseau sign positive). Ca 6.2 mg/dL (measured), Mg 1.2 mg/dL, PTH 2 pg/mL.

Diagnosis: Severe symptomatic postoperative hypocalcemia with hypomagnesemia. Give monitored IV calcium promptly, correct magnesium concurrently using kidney-aware dosing, then individualize oral calcium/active vitamin D. Follow symptoms, ionized calcium, magnesium, phosphate and kidney function; do not delay calcium until magnesium has normalized.

### Vignette 3: Tumor Lysis Syndrome

A 44-year-old with newly diagnosed Burkitt lymphoma (pre-treatment labs): Ca 6.8 mg/dL, PO4 8.2 mg/dL, uric acid 12.5 mg/dL, Cr 1.9 (baseline 0.9), K 6.8 mEq/L.

Diagnosis: Tumor lysis syndrome with AKI and dangerous hyperkalemia. Obtain urgent ECG/monitored care and treat potassium promptly. Tailor fluids to perfusion, urine output and overload risk; coordinate oncology/nephrology urate treatment with G6PD precautions for rasburicase. Avoid routine calcium for asymptomatic hypocalcemia, but treat symptomatic hypocalcemia or calcium-requiring cardiac emergencies. Monitor labs frequently and use urgent KRT for uncontrolled complications; do not add a fixed 600-mg allopurinol regimen automatically.

### Vignette 4: CKD-MBD in Stage 4 CKD

A 72-year-old with CKD Stage 4 (GFR 18): Ca 8.2 mg/dL, PO4 5.1 mg/dL, Albumin 3.8 g/dL, PTH 412 pg/mL (markedly elevated), 1,25-D 18 pg/mL (low).

Interpretation: G4 CKD with hyperphosphatemia and secondary hyperparathyroidism. Confirm trends, review phosphate intake/additives and correct vitamin D deficiency or other modifiable factors. Choose phosphate-lowering treatment for persistent elevation. Consider active vitamin D only if hyperparathyroidism is severe and progressive after those measures, with close calcium/phosphate monitoring. No fixed PTH 35–70 target or calcium–phosphate product goal applies.

------------------------------------------------------------------------

## References

\[1\] Goltzman D, Mannstadt M, Marcocci C. “Physiology of the calcium-parathyroid hormone-vitamin D axis.” *Front Horm Res*. 2018;51:1-13. doi: 10.1159/000486060 [PubMed](https://pubmed.ncbi.nlm.nih.gov/29597231/)

\[2\] Cooper MS, Gittoes NJ. “Diagnosis and management of hypocalcaemia.” *BMJ*. 2008 Jun 7;336(7656):1298-1302. doi: 10.1136/bmj.39582.589433.BE [PubMed](https://pubmed.ncbi.nlm.nih.gov/18535072/)

\[3\] Walker MD, Shane E. Hypercalcemia: A Review. *JAMA*. 2022. [PubMed PMID 36282253](https://pubmed.ncbi.nlm.nih.gov/36282253/)

\[4\] Shoback D. Clinical practice. Hypoparathyroidism. *N Engl J Med*. 2008;359(4):391-403. [DOI](https://doi.org/10.1056/NEJMcp0803050) \| [PubMed](https://pubmed.ncbi.nlm.nih.gov/18650515/)

\[5\] Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. “KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral–Bone Disorder (CKD-MBD).” *Kidney International Supplements*. 2017 Jul;7(1):1-59. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30675420/)

------------------------------------------------------------------------

## Related Resources

- BMP Pattern Recognition Master Guide
- Phosphorus Comprehensive Guide
- Urinalysis Master Diagnostic Algorithm
- CKD Mineral Bone Disease Overview
- Hyperparathyroidism Diagnostic Workup

------------------------------------------------------------------------

*Last updated: 2026-02-28 \| Board-review quality reference. For acute symptomatic hypocalcemia, never delay IV calcium awaiting confirmatory labs.*


---

[Website version](https://urinenephrology.org/student-resources/electrolyte-acid-base/calcium-phosphorus-student-handout.html) · Markdown synchronized October 3, 2026.